Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Inclusion Criteria:

1. Written informed consent.

2. Aged between 12 and 65, both genders

3. Positive suggestive clinical history of intermittent or persistent moderate tosevere rhinitis /rhinoconjunctivitis according to ARIA classification, with orwithout moderate intermittent or persistent asthma,according to GEMA 5.0, due tograss and cupressaceae pollen.

4. Subjects with a positive skin prick-test (wheal size >5 mm diameter) to astandardized mixed extract of grass pollen (Phleum pratense, Holcus lanatus,Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne) or to one of themolecular components of the mixture and to a cupressaceae extract. In addition, thelargest diameter of the papules must be greater than or equal to that of thehistamine.

5. Specific IgE > 3,5 KU/L , against grass (preferably Phleum pratense) andcupressaceae pollen (InmunoCAP® o Immulite).

6. Women of childbearing age (from menarche) must present a urine pregnancy test with anegative result at the time of joining the trial.

7. Women of childbearing potential participating in the trial, should commit to usingan appropriate method of contraception. Medically acceptable methods ofcontraception are intrauterine devices placed at least 3 months in advance, surgicalsterilization (for example, tubal ligation), barrier methods, or the use of oralcontraceptives.

8. Subjects capable of complying with the dosing regimen.

9. Subjects who own a smartphone for symptom registration and medication.

10. Subjects with a negative prick test to coestational pollens. In the case specificIgE is available, the result should be <3,5 kU/L and without relevant symptomatology

11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliumsand fungus). In the case specific IgE is available, the result should be <3,5 kU/Land without relevant symptomatology.

Exclusion Criteria:

1. Subjects with positive prick test to other aeroallergens except for sensitisation toepithelia with occasional exposure and symptoms.

2. Subjects with positive prick test to other aeroallergens except for sensitisation topollen noncoseasonal with cupressus or grasses.

3. Subjects who have received prior immunotherapy in the preceding 5 years for any ofthe allergens tested or a cross-reactive allergen or are currently receivingimmunotherapy with any allergen.

4. Subjects in which immunotherapy may be subject to an absolute generalcontraindication according to the criteria of the Immunotherapy Committee of theSpanish Society of Allergy and Clinical Immunology and the European Allergy andClinical Immunology Immunotherapy Subcommittee.

5. Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1 <70% with respect to the reference value despite adequate pharmacological treatmentat the time of inclusion in the trial. Likewise, subjects with intermittent orpersistent rhinitis / rhinoconjunctivitis with severe symptoms in which thesuspension of oral or systemic antihistamine treatment is contraindicated.

6. Subjects who have previously had a severe secondary reaction during the prick testdiagnostic skin test.

7. Subjects treated with beta-blockers.

8. Clinically unstable subjects at the time of inclusion in the trial (acute asthmaticexacerbation, respiratory infection, febrile process, acute urticaria, etc.).

9. Subjects with active chronic urticaria, severe dermographism, severe atopicdermatitis, sunburn, active psoriasis with lesions in areas where skin tests will beperformed, or a history of hereditary angioedema.

10. Subjects who have any pathology in which adrenaline administration iscontraindicated (hyperthyroidism, HTN, heart disease, etc.).

11. Subjects with any other disease not related to moderate rhinoconjunctivitis orasthma, but potentially serious and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multioperatedpatients, kidney disease,).

12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or witha diagnosis of immunodeficiencies.

13. Subject whose condition prevents from offering cooperation and/ or who has severepsychiatric disorders.

14. Subjects with a known allergy to components of the investigational medicinal productother than the allergen.

15. Subjects with lower respiratory diseases other than asthma such as emphysema orbronchiectasis.

16. Subjects who are direct relatives of the researchers.

17. Pregnant or lactating women.